FDG PET/CT Findings of Erdheim-Chester Disease: Radiologic Response to a Novel Treatment Regimen
Document Type
Journal Article
Publication Date
5-1-2018
Journal
Clinical Nuclear Medicine
Volume
43
Issue
5
DOI
10.1097/RLU.0000000000002033
Keywords
BRAF inhibitor; Erdheim-Chester disease; histiocytosis; macrophages
Abstract
© 2018 Wolters Kluwer Health, Inc. All rights reserved. Erdheim-Chester disease (ECD) is a rare form of non-Langerhans histiocytosis with deposition of lipid-laden macrophages in numerous organs. A 74-year-old man with a history of coronary artery disease, hypertension, and hyperlipidemia presented with nonspecific symptoms including back pain, nausea, vomiting, vertigo, and left leg pain. A neutrophil-predominant elevated WBC count and a bone biopsy revealing histiocytic proliferation positive for CD68 and CD163 and negative for S100 was noted. FDG PET/CT, MRA, and CTA images were obtained. We review the radiologic hallmarks of ECD and demonstrate the radiologic manifestations of response to combined BRAF and MEK inhibitor treatment.
APA Citation
Akin, E., Osman, M., & Ellenbogen, A. (2018). FDG PET/CT Findings of Erdheim-Chester Disease: Radiologic Response to a Novel Treatment Regimen. Clinical Nuclear Medicine, 43 (5). http://dx.doi.org/10.1097/RLU.0000000000002033